DiaSorin SpA
Nineveh Sarggis has held various roles in the field of sales and marketing, primarily in the medical device and diagnostics industry. Nineveh'smost recent position was as a Director at DiaSorin, where they oversaw commercial labs in the eastern region of the United States. Prior to that, they worked as a Commercial Lab Executive at DiaSorin. Nineveh also served as a Senior Molecular Account Executive at GenMark Diagnostics and a Regional Sales Manager at T2 Biosystems. In addition, they held roles at OpGen, Inc. as a Clinical Accounts Executive, and at bioMerieux as a Sr. US Clinical Marketing Manager and a Senior Account Executive for the Microbiology Business. Before entering the medical industry, they gained experience as a Sales Representative at Kerr Corporation and Paychex, and as a Training Manager at Siemens Healthcare. Overall, Nineveh Sarggis has a strong background in sales and marketing leadership, particularly in the diagnostics and medical device sectors.
Nineveh Sarggis obtained a Bachelor's degree in Biological Sciences from the University of the Pacific between 1988 and 1991.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.